Shopping Cart
- Remove All
- Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $38 | In Stock | |
5 mg | $89 | In Stock | |
10 mg | $133 | In Stock | |
25 mg | $251 | In Stock | |
50 mg | $437 | In Stock | |
100 mg | $646 | In Stock | |
500 mg | $1,380 | In Stock |
Description | JP1302 is a selective α2C adrenoceptor antagonist with a Kb value of 16 nM and a Ki of 28 nM for human α2C receptors.JP1302 has antidepressant activity, disrupts the FACT complex and degrades histone H1.JP1302 has been used in the study of neuropsychiatric disorders, acute renal failure, and renal injury. |
In vitro | JP1302 exhibits approximately a 100-fold greater affinity compared to α2A or α2B.[1] |
In vivo | JP1302 (5 μmol/kg; once; Sprague-Dawley rats) is capable of complete reversal of the impairment in PPI induced in Sprague-Dawley rats by the psychotomimetic NMDA receptor antagonist, phencyclidine, and similar results are found in Wistar rats.[1] JP1302 (1-10 μmol/kg) decreases immobility time in the FST to a level similar to that seen with 10-30 μmol/kg of the antidepressant Desipramine.[1] JP1302 (3 mg/kg; IV, pre-treatment: administered 5 min before the induction of ischemia, post-treatment: injected 45 min after the initiation of reperfusion; once; Male Sprague Dawley rats ) significantly ameliorated renal dysfunction in the rats at 24 h after reperfusion. post-ischemic administration of JP-1302 significantly ameliorated renal dysfunction, and histological damage and reduced apoptotic cells and pro-inflammatory cytokine mRNA expression.[3] |
Molecular Weight | 368.47 |
Formula | C24H24N4 |
Cas No. | 80259-18-3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO: < 1 mg/mL (insoluble or slightly soluble) H2O: < 44.14 mg/mL |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.